DMAC
DiaMedica TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Positive clinical readouts or a strategic partnership plus non-dilutive funding lead to rapid re-rating; upside driven by licensing/milestone value.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +5.4.
What can break
Clinical failure or need for heavy dilution compresses equity value materially; low liquidity amplifies downside.
Momentum
88
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.57 · Bull $1.08 · Bear $0.17
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-13 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $15.59
Why
Momentum88 · Δ7d +5.4
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
88
26% active weight
Current posture
7d trendFlat
Δ7d
+5.4
Δ21d
+70.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 87.7 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$381.49M
Beta
1.10
Shares Out
53.88M
P/E (TTM) · Derived
-10.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-11.14
Rev YoY
-100.0%
EPS YoY
+3.8%
Gross Margin
+97.7%
Op Margin
-
Net Debt
-$59.65M
Current Ratio
9.11
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology